Kolexia
Geoerger Birgit Pédiatrie
Geoerger Birgit
Pédiatrie
Gustave-Roussy
Villejuif, France
291 Activités
9 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Gliome Neuroblastome Sarcomes Rhabdomyosarcome Récidive tumorale locale Lymphomes Tumeurs du cerveau Mélanome Sarcome d'Ewing

Collaborateurs

Voir plus
Vassal Gilles
Vassal Gilles
Gustave-Roussy, Villejuif, France
Aerts Isabelle
Aerts Isabelle
Clcc Institut Curie, Paris, France
Doz Francois
Doz Francois
Clcc Institut Curie, Paris, France
Schleiermacher Gudrun
Schleiermacher Gudrun
Clcc Institut Curie, Paris, France

Industries

Voir plus
Novartis
7 collaboration(s)
Dernière en 2022
Roche
6 collaboration(s)
Dernière en 2023
Boehringer Ingelheim
3 collaboration(s)
Dernière en 2021
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Twinning to reduce research and innovation inequalities in paediatric solid tumours across Europe
EJC paediatric oncology   01 juin 2024
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy: A Multi-center, Open-label, Non-randomized, Phase I Dose Escalation Study of Regorafenib (BAY 73-4506) in Pediatric Subjects With Solid Malignant Tumors That Are Recurrent or Refractory to Standard Therapy
Essai Clinique (Bayer)   18 mars 2024
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051): A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Essai Clinique (Merck & Co.)   06 mars 2024
NAVIGATE: A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion
Essai Clinique (Bayer)   19 février 2024
SCOUT: A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
Essai Clinique (Bayer)   19 février 2024
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
European journal of cancer (Oxford, England : 1990)   15 février 2024
Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common and transcriptional silencing across advanced pediatric solid cancers.
Frontiers in immunology   22 janvier 2024
Precision Medicine for Childhood Cancer: Current Limitations and Future Perspectives.
JCO precision oncology   15 janvier 2024
METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors.
European journal of cancer (Oxford, England : 1990)   06 janvier 2024
CREATE: Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")
Essai Clinique (Pfizer)   08 décembre 2023